Butaperazine
Typical antipsychotic
From Wikipedia, the free encyclopedia
Butaperazine (Repoise, Tyrylen) is a typical antipsychotic of the phenothiazine class.[2] It was approved in 1967, and possibly discontinued in the 1980s.
| |
| Clinical data | |
|---|---|
| ATC code | |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEBI | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.010.450 |
| Chemical and physical data | |
| Formula | C24H31N3OS |
| Molar mass | 409.59 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
| (verify) | |
Synthesis
Butaperazine can be synthesized starting from 2-butyrylphenothiazine (1).[3] It is prepared in a manner that is comparable to the method used in the synthesis of propiomazine and propiopromazine.[clarification needed] The phenothiazine is alkylated with 1-(γ-chloropropyl)-4-methylpiperazine (2), which is prepared in the conventional way by alkylating 1-methylpiperazine with 1-bromo-3-chloropropane.